Gonzalez-Alvarez, I.; Ruiz-Picazo, A.; Selles-Talavera, R.; Figueroa-Campos, A.; Merino, V.; Bermejo, M.; Gonzalez-Alvarez, M.
In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug. Pharmaceutics 2024, 16, 390.
https://doi.org/10.3390/pharmaceutics16030390
AMA Style
Gonzalez-Alvarez I, Ruiz-Picazo A, Selles-Talavera R, Figueroa-Campos A, Merino V, Bermejo M, Gonzalez-Alvarez M.
In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug. Pharmaceutics. 2024; 16(3):390.
https://doi.org/10.3390/pharmaceutics16030390
Chicago/Turabian Style
Gonzalez-Alvarez, Isabel, Alejandro Ruiz-Picazo, Ruben Selles-Talavera, Andres Figueroa-Campos, Virginia Merino, Marival Bermejo, and Marta Gonzalez-Alvarez.
2024. "In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug" Pharmaceutics 16, no. 3: 390.
https://doi.org/10.3390/pharmaceutics16030390
APA Style
Gonzalez-Alvarez, I., Ruiz-Picazo, A., Selles-Talavera, R., Figueroa-Campos, A., Merino, V., Bermejo, M., & Gonzalez-Alvarez, M.
(2024). In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug. Pharmaceutics, 16(3), 390.
https://doi.org/10.3390/pharmaceutics16030390
